Key Takeaways
- Oscar Health delivered Q2 net earnings of $361.8 million, translating to $1.10 per diluted share, compared to an 89-cent loss in the prior-year period
- Total revenue climbed 70% from the previous year to reach $4.88 billion, surpassing analyst projections of $4.73 billion
- The company’s medical loss ratio declined to 79.2%, a significant improvement from 91.1% recorded in Q2 2025
- Management elevated full-year earnings from operations guidance to a $500 million-$700 million range from the previous $250 million-$450 million outlook
- Despite the impressive results, OSCR shares declined approximately 9% on Thursday following an 8.9% surge in premarket trading
Oscar Health delivered what many consider its most impressive quarterly performance to date Thursday, yet investors responded by sending shares lower.
OSCR declined roughly 9% during Thursday’s session on August 6, erasing a nearly 9% premarket rally. Shares had settled at $30.11 in Wednesday’s close. Even accounting for Thursday’s decline, the stock remains up 110% year-to-date in 2026, dramatically outpacing the S&P 500’s 13% advance.
The health insurer announced Q2 earnings of $1.10 per share, significantly exceeding the analyst consensus forecast of 40 cents. Total revenue jumped 70% to $4.88 billion, topping Wall Street’s $4.73 billion projection.
OSCAR HEALTH $OSCR Q2ā26 EARNINGS HIGHLIGHTS
š¹ Revenue: $4.9B (Est. $4.75B) š¢
š¹ EPS: $1.10 (Est. $0.39) š¢
š¹ Adj EBITDA: $415.3M (Est. $188M) š¢
š¹ Net Income: $361.8M (Est. $156M) š¢FY26 Guide:
š¹ Revenue: $18.7B-$19.0B (Est. $18.62B) š”
š¹ Operating Income: $500M-$700Mā¦ pic.twitter.com/DSJfXJ4Nd4ā Wall St Engine (@wallstengine) August 6, 2026
Looking at the first six months of 2026, Oscar generated net income of $1.04 billion, equivalent to $3.16 per share. This represents a substantial increase from the $46.9 million earned during the corresponding period last year.
Strong MLR Performance Highlights Operational Excellence
The medical loss ratio improved to 79.2% during Q2, declining from 91.1% in the year-ago quarter. This figure came in better than Wall Street’s 81.2% expectation, representing a meaningful operational win. Management attributed the performance to strategic pricing discipline and $164 million in favorable adjustments from prior period reserve development.
Oscar increased its full-year earnings from operations projection to between $500 million and $700 million, marking a substantial upgrade from the earlier $250 million to $450 million guidance range. The company maintained its total revenue forecast at $18.7 billion to $19 billion.
Total membership reached 2.9 million as of June 30, representing 46% growth compared to the prior year. This expansion occurred even as nationwide ACA enrollment contracted by approximately three million members following the expiration of temporary federal subsidies late last year.
Major competitors CVS Health’s Aetna withdrew from the ACA individual marketplace this year. Cigna announced it will exit in 2027. Oscar has pursued the opposite strategy.
Membership Attrition Concerns Weigh on Sentiment
What explains the stock decline? Stephens analyst Raj Kumar identified the potential for membership attrition during the second half of the year as a probable concern.
Membership had already experienced a modest decline from 3.2 million at March 31 to 2.96 million at June 30. CEO Mark Bertolini confirmed during the earnings call that the organization anticipates “further market contraction.”
Kumar observed that possible attrition “could add additional risk” to forward projections. For Oscar, unlike more diversified insurance competitors, the ACA marketplace represents its entire business model.
Baird analyst Michael Ha characterized the results as “an important proof point for the earnings thesis,” while noting that maintaining a position in the stock requires conviction that the ACA marketplace “remains structurally viable as enrollment and market composition evolve.”
The consensus analyst rating on OSCR stands at Hold, with an average price target of $26.09, based on FactSet data.
Bertolini stated the company is moving into the second half of 2026 “from a position of strength, with the technology, scale, and operating discipline to deliver profitable growth.”
The consensus analyst price target of $26.09 remains below the stock’s trading level prior to Thursday’s selloff.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
